Postmarket data from Europe and Chile, announced at the American Diabetes Association conference, offer more support for Medtronic’s faith in its MiniMed 780G system with the Guardian 4 sensor.
“Real-world” experience with Medtronic’s MiniMed 780G system with the Guardian 4 sensor, presented at the American Diabetes Association (ADA) meeting in New Orleans, affirm the encouraging results from the randomized ADAPT trial of the 780G system.
Preliminary results from ADAPT, announced last month, showed type 1 diabetes patients using the 780G system had a better a...
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
